Pre-implantation genetic testing (PGT) plays a crucial role in enhancing success rates and reducing the risk of passing on genetic disorders during in vitro fertilization (IVF). PGT involves screening embryos created through IVF for genetic abnormalities before they are implanted in the uterus, thereby ensuring only healthy embryos are selected for implantation.

There are several ways in which PGT enhances success rates and reduces the risk of genetic disorders. Firstly, PGT can identify embryos that carry genetic mutations or chromosomal abnormalities, allowing for the selection of unaffected embryos for transfer during IVF. This significantly increases the chances of a successful pregnancy and reduces the likelihood of miscarriage or the birth of a child with a genetic disorder.

Advancements in PGT technology have further improved its accuracy and accessibility. One key advancement is the development of comprehensive chromosomal screening techniques such as array comparative genomic hybridization (aCGH) and next-generation sequencing (NGS). These methods provide detailed information about the genetic makeup of embryos, allowing for more accurate identification of genetic abnormalities.

Moreover, the advent of techniques like trophectoderm biopsy, where cells are extracted from the outer layer of the embryo for genetic testing, has improved the accuracy of PGT by avoiding mosaicism (presence of different genetic cell lines in one individual). This ensures that only embryos with a low risk of genetic disorders are selected for transfer.

In terms of accessibility, improvements in PGT technology have led to decreased costs and faster turnaround times for testing